Section Arrow
MGNX.NASDAQ
- MacroGenics
Quotes are at least 15-min delayed:2025/07/21 06:45 EDT
Pre Market
Last
 1.49
+0.01 (+0.68%)
Bid
1.48
Ask
1.78
High 1.5 
Low 1.48 
Volume 1302 
Regular Hours
Last
 1.48
-0.06 (-3.90%)
Day High 
1.595 
Prev. Close
1.54 
1-M High
1.65 
Volume 
381.88K 
Bid
1.48
Ask
1.78
Day Low
1.47 
Open
1.56 
1-M Low
1.185 
Market Cap 
97.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.52 
20-SMA 1.41 
50-SMA 1.48 
52-W High 5.77 
52-W Low 0.98965 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.88/-2.89
Enterprise Value
129.76M
Balance Sheet
Book Value Per Share
1.25
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
148.34M
Operating Revenue Per Share
1.89
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.15 -0.925 -6.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.23 +0.39 +6.68%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:45 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.